The Swiss-based company PreAnalytiX GmbH, is an equally-owned, worldwide joint venture between QIAGEN N.V. and Becton, Dickinson and Company (BD). PreAnalytiX develops manufactures and markets integrated systems for the collection, transport and storage for human sample material, targeting nucleic acid (DNA and RNA) and proteins for molecular diagnostic testing. One core competency of PreAnalytiX is the development and manufacture of sample collection devices for molecular diagnostic applications, for use in health care systems, pharma- and biotechnological research and academia, for various human sample materials. Another core competency is the development of integrated systems for sample collection, transport and storage and extraction of biomolecular targets (RNA, DNA and proteins) for use in diagnostic applications. PreAnalytiX has successfully developed pre-analytical systems for the in-vitro molecular diagnostic market. The PAXgene Blood RNA system was the first system ever that was approved for the use in in-vitro diagnostic applications based on cellular RNA from whole blood samples. The system received the CE mark and FDA clearance in 2005.